Table 1:

Sociodemographic, clinical and pregnancy characteristics of study participants

CharacteristicNo. (%) of participants*
n = 362
Trimester at triage visit
 1st (< 14 weeks’ gestation)< 6 (S)
 2nd (14–28 weeks’ gestation)41 (11.3)
 3rd (≥ 28 weeks’ gestation)320 (88.4)
Symptoms consistent with COVID-19 upon admission to triage57 (15.7)
SARS-CoV-2 infection in pregnancy documented in medical chart§5 (1.4)
Maternal age, yr, mean ± SD32.4 ± 4.9
Parity
 0166 (45.9)
 ≥ 1195 (53.9)
 Missing< 6 (S)
Neighbourhood median family income quintile
 1 (lowest)51 (14.1)
 280 (22.1)
 373 (20.2)
 480 (22.1)
 5 (highest)76 (21.0)
 Missing< 6 (S)
Race and ethnicity
 White203 (56.1)
 Asian28 (7.7)
 Black26 (7.2)
 Other45 (12.4)
 Missing60 (16.6)
Prepregnancy BMI, median (IQR)25.6 (21.9–30.3)
Obese (BMI > 30.0)**
 No228 (63.0)
 Yes86 (23.8)
 Missing48 (13.3)
Substance use during pregnancy††,‡‡
 No323 (89.2)
 Yes35 (9.7)
 Missing< 6 (S)
Anxiety‡‡
 No277 (76.5)
 Yes85 (23.5)
Depression‡‡
 No311 (85.9)
 Yes51 (14.1)
Pre-existing maternal health conditions
 None306 (84.5)
 Asthma44 (12.2)
 Chronic hypertension7 (1.9)
 Diabetes7 (1.9)
Gestational diabetes
 No324 (89.5)
 Yes38 (10.5)
Hypertensive disorder in pregnancy§§
 No314 (86.7)
 Yes48 (13.3)
Antenatal health care provider
 Family physician only24 (6.6)
 Obstetrician only252 (69.6)
 Family physician and obstetrician44 (12.2)
 Midwife31 (8.6)
 Other provider8 (2.2)
 No provider< 6 (S)
 Missing< 6 (S)
Number of fetuses
 Singleton345 (95.3)
 Multiple17 (4.7)
Gestational age at delivery, wk, median (IQR)39.0 (38.0–40.0)
Preterm delivery (< 37 weeks’ gestation)
 No310 (85.6)
 Yes51 (14.1)
 Missing< 6 (S)
Mode of delivery
 Vaginal221 (61.0)
 Cesarean141 (39.0)
 Missing< 6 (S)
Birth outcome
 Live birth361 (99.7)
 Intrapartum stillbirth< 6 (S)
  • Note: BMI = body mass index, IQR = interquartile range, S = suppressed due to small cell size, SD = standard deviation.

  • * Unless indicated otherwise.

  • Trimester of triage visit was calculated using the date that the patient was first enrolled in the study.

  • Participant reported symptoms consistent with COVID-19 on Febrile Respiratory Illness Screening Tool used at hospital entry.

  • § Participant had documentation of a positive SARS-CoV-2 laboratory test result that was reported during pregnancy and within time period of study.

  • Information on race and ethnicity was obtained from the Ontario birth registry (Better Outcomes Registry & Network) and supplemented with medical chart review wherever possible. Racial and ethnic designations were assigned by the provider, sometimes through self-declaration by patients.

  • ** BMI values below 10.3 and above 79.9 were excluded as outliers and set to missing for BMI grouping and obesity.

  • †† Substance use during pregnancy is defined as alcohol, drug or smoking during pregnancy.

  • ‡‡ Self-reported variables obtained from the Ontario birth registry (Better Outcomes Registry & Network).

  • §§ Conditions include eclampsia, gestational hypertension, HELLP (hemolysis, elevated liver enzymes and low platelets), preeclampsia and pre-existing hypertension with superimposed preeclampsia.